CVI Stock Recent News

CVR Energy Q2 Revenue Beats by 4%

- enVVeno is developing the VenoValve as a potential treatment option for the approximately 2.5 million patients in the U.S. suffering from severe deep Chronic Venous Insufficiency - FDA decision expected in 2H'2025 - Access the "What This Means" segment here IRVINE, CA / ACCESS Newswire / August 4, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it participated in a Virtual Investor "What This Means" segment entitled, "enVVeno Medical - Making Veins Work Again - How President Trump's CVI Diagnosis is Raising Awareness." Rob Berman, CEO and Dr. Marc Glickman, CMO of enVVeno Medical discussed the progressive nature of chronic veinous insufficiency and whether President Trump may one day be a candidate for the VenoValve® following U.S. Food and Drug Administration (FDA) approval.

CVR Energy faced weak refining margins and high turnaround costs, but improving crack spreads and cost efficiencies offer cautious optimism for a rebound. Turnaround-related headwinds are largely behind, setting up Q3 for margin improvement, though execution remains a 'show-me story.' I expect dividend resumption in 2026, likely at a lower base, with special dividends possible during strong cycles; balance sheet progress is encouraging.

CVR Energy, Inc. (NYSE:CVI ) Q2 2025 Earnings Conference Call July 31, 2025 1:00 PM ET Company Participants Dane J. Neumann - Executive VP, CFO, Treasurer & Assistant Secretary David L.

CVR Energy (CVI) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.09 per share a year ago.

Carl Icahn-backed CVR Energy on Wednesday named Mark Pytosh as chief executive officer and appointed Brett Icahn to its board.

SUGAR LAND, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- CVR Energy, Inc. (NYSE: CVI, “CVR Energy” or the “Company”) today announced second quarter 2025 net loss attributable to CVR Energy stockholders of $114 million, or $1.14 per diluted share, compared to second quarter 2024 net income attributable to CVR Energy stockholders of $21 million, or 21 cents per diluted share. Adjusted loss for the second quarter of 2025 was 23 cents per diluted share, compared to adjusted earnings per diluted share of 9 cents in the second quarter of 2024. Net loss for the second quarter of 2025 was $90 million, compared to net income of $38 million in the second quarter of 2024. Second quarter 2025 EBITDA loss was $24 million, compared to second quarter 2024 EBITDA of $103 million. Adjusted EBITDA for the second quarter of 2025 was $99 million, compared to adjusted EBITDA of $87 million in the second quarter of 2024.

Here's a preview of what to expect from energy stocks CRK, CVI, PUMP, AM and AR ahead of their quarterly earnings reports, set to be released tomorrow.

CVR (CVI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BEAUFORT, S.C.--(BUSINESS WIRE)-- #CVD--A new report published by THE SAGE GROUP quantifies CVD prevalence and incidence for the 2020-2040 period. “Chronic venous disease afflicts 1.5 times as many people as all cardiovascular diseases combined, and five times more than those with diabetes. It is one of the most prevalent chronic diseases. However, CVD is significantly underestimated, underdiagnosed and undertreated,” stated Mary L. Yost, President. CVD represents a spectrum of medical conditions invo.